Expression and role of p16 andGLUT1 in malignant diseases and lung cancer: A review
| Autor: | Aldo Pezzuto, Alberto Ricci, Alessandra Pagliuca, Michela D'Ascanio, Elisabetta Carico |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Male
0301 basic medicine Pulmonary and Respiratory Medicine glucose transporters lung cancer p16 expression Lung Neoplasms Cell cycle checkpoint Mini Review medicine.disease_cause lcsh:RC254-282 03 medical and health sciences 0302 clinical medicine medicine Humans Lung cancer Cyclin-Dependent Kinase Inhibitor p16 Glucose Transporter Type 1 biology Kinase business.industry Glucose transporter General Medicine Cell cycle Prognosis lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease 030104 developmental biology Oncology 030220 oncology & carcinogenesis Cancer cell Cancer research biology.protein Female GLUT1 Carcinogenesis business |
| Zdroj: | Thoracic Cancer, Vol 11, Iss 11, Pp 3060-3070 (2020) Thoracic Cancer |
| ISSN: | 1759-7714 1759-7706 |
| Popis: | Non‐small cell lung cancer (NSCLC) is the leading cause of cancer death and in most cases it is often diagnosed at an advanced stage. Many genetic and microenvironmental factors are able to modify the cell cycle inducing carcinogenesis and tumor growth. Among the metabolic and genetic factors that come into play in carcinogenesis and tumor cell differentiation and growth there are two different proteins that should be considered which are glucose transporters (GLUTs) and p16INK4 The first are glucose transporters which are strongly involved in tumor metabolism, notably accelerating cancer cell metabolism both in aerobic and anaerobic conditions. There are different subtypes of GLUT family factors of which GLUT 1 is the most important and widely expressed. By contrast, p16 is mainly a tumor‐suppressor protein that acts on cyclin‐dependent kinase favoring cell cycle arrest in the G1 phase. Our search focused on the action of the aforementioned factors. This review highlights the role of p16 and GLUT‐1 and GLUTs proteins in malignancies especially in lung cancer, focusing on the pathways activated leading to cell cycle dysregulation, cancer growth and migration. Since they have a clinical prognostic value, they may become targets for novel therapies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |